| Project/Area Number |
22501033
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor diagnosis
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NISHIYAMA Masahiko 群馬大学, 院医学系研究科, 教授 (20198526)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
FUJIWARA Keiichi 埼玉医科大学, 医学部, 教授 (20238629)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 薬効評価と予測 / 卵巣癌 / 腹膜癌 / 遺伝子多型 / パクリタキセル / 副作用 / 治療効果予測 / 薬物動態学的解析 / バイオマーカー / 遺伝子発現 |
|---|
| Research Abstract |
In a phase II clinical trial of weekly paclitaxel (TXL)/ IP carboplatin (CBDCA) administration on ovarian and peritoneal cancers, we determined various genetic polymorphisms and analyzed their associations with pharmacokinetics (PK) parameters of TXL at first administration and adverse effects. We found that GSTM1 deletion, ABCB1 2677G>T/A and CYP3A5 rs776746 gene polymorphisms were significantly associated with the PK parameters, appearance of grade 4 neutropenia and extent of leukopenia.
|
